Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa - 14/03/14
Abstract |
Background |
Interferon-alfa is used in the treatment of primary cutaneous B-cell lymphoma (PCBCL). Therapy with interferon-alfa has thus far been reported solely in case reports and small case series, mostly describing intralesional use.
Objective |
We sought to evaluate efficacy, response rate, time to response, duration of response, and safety of subcutaneously administered interferon-alfa for the treatment of cutaneous B-cell lymphoma.
Methods |
We conducted a retrospective chart analysis of patients given the diagnosis of PCBCL and treated with interferon-alfa subcutaneously at a tertiary referral center.
Results |
Fifteen patients with indolent subtypes of PCBCL were identified. The overall response rate was 66.7%; all responding patients went into complete remission. Response was not significantly associated with the maximum tolerated dose. Within the median follow-up time of 40 months, 90% of the responders experienced a relapse; median duration of response was 15.5 months. Adverse events were predominantly mild and in no case led to cessation of therapy.
Limitations |
Retrospective nature of the analysis and small number of patients because of scarcity of the disease are limitations.
Conclusion |
Treatment of indolent PCBCL with subcutaneously injected interferon-alfa demonstrated good response rates and tolerability. Response was not dose dependent. Relapses were observed in nearly all responding patients raising the question of interferon-alfa maintenance therapy in PCBCL.
Le texte complet de cet article est disponible en PDF.Key words : follicle center lymphoma, interferon-alfa, marginal zone B-cell lymphoma, primary cutaneous B-cell lymphoma, systemic treatment
Abbreviations used : AE, CR, EORTC, PCBCL, PCFCL, PCMZL
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 70 - N° 4
P. 709-715 - avril 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?